nogapendekin alfa inbakicept-pmln

AssetAlso called Nogapendekin Alfa, N-803, ANKTIVA, NAI

IL-15 superagonist enhances natural killer and T-cell responses to support vaccine-mediated cancer prevention.

Stage
Approved
Modality
Protein or enzyme
Target
IL2RB
26
Indications
14
Trials
3
Developers

Approved by the FDA on Apr 22, 2024 (BLA761336). 2 approvals stand. FDA

Indications

26
  • Bcg-unresponsive non-muscle invasive bladder cancer

    Approved, FDA

  • Bladder cancer

    Approved, news.google.com

  • Bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ

    Approved, businesswire.com

23 more

In the full profile

  • Target and mechanism4
  • Owner and partners4
  • Trials14
  • Evidence for its targets3
  • Competitors12
  • Signals11

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets